Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolaños, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella & 10 others Murat Terzi, Jeannette Lechner-Scott, Vincent Van Pesch, Raymond Hupperts, José Luis Sánchez-Menoyo, Suzanne Hodgkinson, C. Rózsa, Freek Verheul, Helmut Butzkueven, Tomas Kalincik

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE: To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on relapse rate, disability, and treatment persistence in patients with activeMS. DESIGN, SETTING, AND PARTICIPANTS: Matched retrospective analysis of data collected prospectively from MSBase, an international, observational cohort study. The MSBase cohort represents a population of patients with MS monitored at large MS centers. The analyzed data were collected between July 1996 and April 2014. Participants included patients with relapsing-remittingMS who were switching therapy to fingolimod or injectable immunomodulators up to 12 months after on-treatment clinical disease activity (relapse or progression of disability), matched on demographic and clinical variables. Median follow-up duration was 13.1 months (range, 3-80). Indication and attrition bias were controlled with propensity score matching and pairwise censoring, respectively. Head-to-head analyses of relapse and disability outcomes used paired, weighted, negative binomial models or frailty proportional hazards models adjusted formagnetic resonance imaging variables. Sensitivity analyses were conducted. EXPOSURES: Patients had received fingolimod, interferon beta, or glatiramer acetate for a minimum of 3 months following a switch of immunomodulatory therapy. MAIN OUTCOMES AND MEASURES: Annualized relapse rate and proportion of relapse-free patients, as well as the proportion of patients without sustained disability progression. RESULTS Overall, 379 patients in the injectable group were matched to 148 patients in the fingolimod group. The fingolimod group had a lower mean annualized relapse rate (0.31 vs 0.42; 95%CI, 0.02-0.19; P = .009), lower hazard of first on-treatment relapse (hazard ratio [HR], 0.74; 95%CI, 0.56-0.98; P = .04), lower hazard of disability progression (HR, 0.53; 95%CI, 0.31-0.91; P = .02), higher rate of disability regression (HR, 2.0; 95%CI, 1.2-3.3; P = .005), and lower hazard of treatment discontinuation (HR, 0.55; P = .04) compared with the injectable group. CONCLUSIONS AND RELEVANCE: Switching from injectable immunomodulators to fingolimod is associated with fewer relapses, more favorable disability outcomes, and greater treatment persistence compared with switching to another injectable preparation following on-treatment activity of MS.

Original languageEnglish
Pages (from-to)405-413
Number of pages9
JournalJAMA Neurology
Volume72
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Interferon-beta
Multiple Sclerosis
Recurrence
Immunologic Factors
Injections
Therapeutics
Fingolimod Hydrochloride
Glatiramer Acetate
Relapse
Propensity Score
Immunomodulation
Hazard
Statistical Models
Proportional Hazards Models
Interferons
Observational Studies
Cohort Studies
Research Design
Demography
Physicians

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Medicine(all)

Cite this

He, A., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., ... Kalincik, T. (2015). Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurology, 72(4), 405-413. https://doi.org/10.1001/jamaneurol.2014.4147

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. / He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Grammond, Pierre; Duquette, Pierre; Girard, Marc; Pucci, Eugenio; Iuliano, Gerardo; Alroughani, Raed; Oreja-Guevara, Celia; Fernandez-Bolaños, Ricardo; Grand'Maison, Francois; Sola, Patrizia; Spitaleri, Daniele; Granella, Franco; Terzi, Murat; Lechner-Scott, Jeannette; Van Pesch, Vincent; Hupperts, Raymond; Sánchez-Menoyo, José Luis; Hodgkinson, Suzanne; Rózsa, C.; Verheul, Freek; Butzkueven, Helmut; Kalincik, Tomas.

In: JAMA Neurology, Vol. 72, No. 4, 01.04.2015, p. 405-413.

Research output: Contribution to journalArticle

He, A, Spelman, T, Jokubaitis, V, Havrdova, E, Horakova, D, Trojano, M, Lugaresi, A, Izquierdo, G, Grammond, P, Duquette, P, Girard, M, Pucci, E, Iuliano, G, Alroughani, R, Oreja-Guevara, C, Fernandez-Bolaños, R, Grand'Maison, F, Sola, P, Spitaleri, D, Granella, F, Terzi, M, Lechner-Scott, J, Van Pesch, V, Hupperts, R, Sánchez-Menoyo, JL, Hodgkinson, S, Rózsa, C, Verheul, F, Butzkueven, H & Kalincik, T 2015, 'Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis', JAMA Neurology, vol. 72, no. 4, pp. 405-413. https://doi.org/10.1001/jamaneurol.2014.4147
He, Anna ; Spelman, Tim ; Jokubaitis, Vilija ; Havrdova, Eva ; Horakova, Dana ; Trojano, Maria ; Lugaresi, Alessandra ; Izquierdo, Guillermo ; Grammond, Pierre ; Duquette, Pierre ; Girard, Marc ; Pucci, Eugenio ; Iuliano, Gerardo ; Alroughani, Raed ; Oreja-Guevara, Celia ; Fernandez-Bolaños, Ricardo ; Grand'Maison, Francois ; Sola, Patrizia ; Spitaleri, Daniele ; Granella, Franco ; Terzi, Murat ; Lechner-Scott, Jeannette ; Van Pesch, Vincent ; Hupperts, Raymond ; Sánchez-Menoyo, José Luis ; Hodgkinson, Suzanne ; Rózsa, C. ; Verheul, Freek ; Butzkueven, Helmut ; Kalincik, Tomas. / Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. In: JAMA Neurology. 2015 ; Vol. 72, No. 4. pp. 405-413.
@article{33073775a3de4265b1ec6b6991e43d0c,
title = "Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis",
abstract = "IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE: To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on relapse rate, disability, and treatment persistence in patients with activeMS. DESIGN, SETTING, AND PARTICIPANTS: Matched retrospective analysis of data collected prospectively from MSBase, an international, observational cohort study. The MSBase cohort represents a population of patients with MS monitored at large MS centers. The analyzed data were collected between July 1996 and April 2014. Participants included patients with relapsing-remittingMS who were switching therapy to fingolimod or injectable immunomodulators up to 12 months after on-treatment clinical disease activity (relapse or progression of disability), matched on demographic and clinical variables. Median follow-up duration was 13.1 months (range, 3-80). Indication and attrition bias were controlled with propensity score matching and pairwise censoring, respectively. Head-to-head analyses of relapse and disability outcomes used paired, weighted, negative binomial models or frailty proportional hazards models adjusted formagnetic resonance imaging variables. Sensitivity analyses were conducted. EXPOSURES: Patients had received fingolimod, interferon beta, or glatiramer acetate for a minimum of 3 months following a switch of immunomodulatory therapy. MAIN OUTCOMES AND MEASURES: Annualized relapse rate and proportion of relapse-free patients, as well as the proportion of patients without sustained disability progression. RESULTS Overall, 379 patients in the injectable group were matched to 148 patients in the fingolimod group. The fingolimod group had a lower mean annualized relapse rate (0.31 vs 0.42; 95{\%}CI, 0.02-0.19; P = .009), lower hazard of first on-treatment relapse (hazard ratio [HR], 0.74; 95{\%}CI, 0.56-0.98; P = .04), lower hazard of disability progression (HR, 0.53; 95{\%}CI, 0.31-0.91; P = .02), higher rate of disability regression (HR, 2.0; 95{\%}CI, 1.2-3.3; P = .005), and lower hazard of treatment discontinuation (HR, 0.55; P = .04) compared with the injectable group. CONCLUSIONS AND RELEVANCE: Switching from injectable immunomodulators to fingolimod is associated with fewer relapses, more favorable disability outcomes, and greater treatment persistence compared with switching to another injectable preparation following on-treatment activity of MS.",
author = "Anna He and Tim Spelman and Vilija Jokubaitis and Eva Havrdova and Dana Horakova and Maria Trojano and Alessandra Lugaresi and Guillermo Izquierdo and Pierre Grammond and Pierre Duquette and Marc Girard and Eugenio Pucci and Gerardo Iuliano and Raed Alroughani and Celia Oreja-Guevara and Ricardo Fernandez-Bola{\~n}os and Francois Grand'Maison and Patrizia Sola and Daniele Spitaleri and Franco Granella and Murat Terzi and Jeannette Lechner-Scott and {Van Pesch}, Vincent and Raymond Hupperts and S{\'a}nchez-Menoyo, {Jos{\'e} Luis} and Suzanne Hodgkinson and C. R{\'o}zsa and Freek Verheul and Helmut Butzkueven and Tomas Kalincik",
year = "2015",
month = "4",
day = "1",
doi = "10.1001/jamaneurol.2014.4147",
language = "English",
volume = "72",
pages = "405--413",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

AU - He, Anna

AU - Spelman, Tim

AU - Jokubaitis, Vilija

AU - Havrdova, Eva

AU - Horakova, Dana

AU - Trojano, Maria

AU - Lugaresi, Alessandra

AU - Izquierdo, Guillermo

AU - Grammond, Pierre

AU - Duquette, Pierre

AU - Girard, Marc

AU - Pucci, Eugenio

AU - Iuliano, Gerardo

AU - Alroughani, Raed

AU - Oreja-Guevara, Celia

AU - Fernandez-Bolaños, Ricardo

AU - Grand'Maison, Francois

AU - Sola, Patrizia

AU - Spitaleri, Daniele

AU - Granella, Franco

AU - Terzi, Murat

AU - Lechner-Scott, Jeannette

AU - Van Pesch, Vincent

AU - Hupperts, Raymond

AU - Sánchez-Menoyo, José Luis

AU - Hodgkinson, Suzanne

AU - Rózsa, C.

AU - Verheul, Freek

AU - Butzkueven, Helmut

AU - Kalincik, Tomas

PY - 2015/4/1

Y1 - 2015/4/1

N2 - IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE: To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on relapse rate, disability, and treatment persistence in patients with activeMS. DESIGN, SETTING, AND PARTICIPANTS: Matched retrospective analysis of data collected prospectively from MSBase, an international, observational cohort study. The MSBase cohort represents a population of patients with MS monitored at large MS centers. The analyzed data were collected between July 1996 and April 2014. Participants included patients with relapsing-remittingMS who were switching therapy to fingolimod or injectable immunomodulators up to 12 months after on-treatment clinical disease activity (relapse or progression of disability), matched on demographic and clinical variables. Median follow-up duration was 13.1 months (range, 3-80). Indication and attrition bias were controlled with propensity score matching and pairwise censoring, respectively. Head-to-head analyses of relapse and disability outcomes used paired, weighted, negative binomial models or frailty proportional hazards models adjusted formagnetic resonance imaging variables. Sensitivity analyses were conducted. EXPOSURES: Patients had received fingolimod, interferon beta, or glatiramer acetate for a minimum of 3 months following a switch of immunomodulatory therapy. MAIN OUTCOMES AND MEASURES: Annualized relapse rate and proportion of relapse-free patients, as well as the proportion of patients without sustained disability progression. RESULTS Overall, 379 patients in the injectable group were matched to 148 patients in the fingolimod group. The fingolimod group had a lower mean annualized relapse rate (0.31 vs 0.42; 95%CI, 0.02-0.19; P = .009), lower hazard of first on-treatment relapse (hazard ratio [HR], 0.74; 95%CI, 0.56-0.98; P = .04), lower hazard of disability progression (HR, 0.53; 95%CI, 0.31-0.91; P = .02), higher rate of disability regression (HR, 2.0; 95%CI, 1.2-3.3; P = .005), and lower hazard of treatment discontinuation (HR, 0.55; P = .04) compared with the injectable group. CONCLUSIONS AND RELEVANCE: Switching from injectable immunomodulators to fingolimod is associated with fewer relapses, more favorable disability outcomes, and greater treatment persistence compared with switching to another injectable preparation following on-treatment activity of MS.

AB - IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE: To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on relapse rate, disability, and treatment persistence in patients with activeMS. DESIGN, SETTING, AND PARTICIPANTS: Matched retrospective analysis of data collected prospectively from MSBase, an international, observational cohort study. The MSBase cohort represents a population of patients with MS monitored at large MS centers. The analyzed data were collected between July 1996 and April 2014. Participants included patients with relapsing-remittingMS who were switching therapy to fingolimod or injectable immunomodulators up to 12 months after on-treatment clinical disease activity (relapse or progression of disability), matched on demographic and clinical variables. Median follow-up duration was 13.1 months (range, 3-80). Indication and attrition bias were controlled with propensity score matching and pairwise censoring, respectively. Head-to-head analyses of relapse and disability outcomes used paired, weighted, negative binomial models or frailty proportional hazards models adjusted formagnetic resonance imaging variables. Sensitivity analyses were conducted. EXPOSURES: Patients had received fingolimod, interferon beta, or glatiramer acetate for a minimum of 3 months following a switch of immunomodulatory therapy. MAIN OUTCOMES AND MEASURES: Annualized relapse rate and proportion of relapse-free patients, as well as the proportion of patients without sustained disability progression. RESULTS Overall, 379 patients in the injectable group were matched to 148 patients in the fingolimod group. The fingolimod group had a lower mean annualized relapse rate (0.31 vs 0.42; 95%CI, 0.02-0.19; P = .009), lower hazard of first on-treatment relapse (hazard ratio [HR], 0.74; 95%CI, 0.56-0.98; P = .04), lower hazard of disability progression (HR, 0.53; 95%CI, 0.31-0.91; P = .02), higher rate of disability regression (HR, 2.0; 95%CI, 1.2-3.3; P = .005), and lower hazard of treatment discontinuation (HR, 0.55; P = .04) compared with the injectable group. CONCLUSIONS AND RELEVANCE: Switching from injectable immunomodulators to fingolimod is associated with fewer relapses, more favorable disability outcomes, and greater treatment persistence compared with switching to another injectable preparation following on-treatment activity of MS.

UR - http://www.scopus.com/inward/record.url?scp=84928169402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928169402&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2014.4147

DO - 10.1001/jamaneurol.2014.4147

M3 - Article

VL - 72

SP - 405

EP - 413

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 4

ER -